Shoko Akiyama

5PUBLICATIONS
18CO-AUTHORS
Epidemiological modellingEpidemiological methodsPredictive and prognostic markersPacific Peoples and disabilityPacific Peoples epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 15, 2026
Correction: Akiyama et al. Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. J. Clin. Med. 2025, 14, 4697.

|Jul 12, 2025
Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan.

Shoko Akiyama, Kenji Oda, Hiroko Mizohata

|Dec 13, 2023
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.

Alexandrosz Czira, Shoko Akiyama, Takeo Ishii

|Sep 30, 2021
Prevalence and Characteristics of Individuals with Preserved Ratio Impaired Spirometry (PRISm) and/or Impaired Lung Function in Japan: The OCEAN Study.

Toshihiko Kaise, Eishin Sakihara, Kentaro Tamaki

|Jun 25, 2021
Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study.

Kentaro Tamaki, Eishin Sakihara, Hiroaki Miyata

Pageof 1

Frequent Collaborators

3 joint publications

Kenichi Hashimoto

2 joint publications

Ryosuke Tawara

2 joint publications

Bruce E Miller

2 joint publications

Ruth Tal-Singer